Contravir Pharmaceut (CTRV) 1.08 $CTRV
Center Point Clinical Services Signs Partnership Agreement with ContraVir Pharmaceuticals
PR Newswire - Wed Jun 29, 6:00AM CDT
Center Point Clinical Services, provider of specialty clinical research solutions including the signature Clinical Trials Research Pharmacist (CTRP®) solution, announced today that it is renewing its partnering agreement with ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies. Under the terms of the agreement, Center Point will continue to provide its CTRP solution to support the clinical sites participating in ContraVir's Phase 3, randomized study of FV-100, in development as a fast-acting, low-dose, once-daily, oral antiviral therapy for the treatment of herpes zoster, or shingles.
CTRV: 1.08 (-0.04)
ContraVir Doses First Patients in Head-to-Head Study of CMX157 vs. Viread® for Treating Hepatitis B
PR Newswire - Tue Jun 21, 5:29AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has dosed the first patients with chronic hepatitis B in its head-to-head Phase 2a study comparing ContraVir's CMX157 to tenofovir DF (TDF, marketed by Gilead Sciences, Inc. as Viread®). The study is the first to directly compare lower doses of CMX157 to the standard daily dose of Viread in hepatitis B patients, and will evaluate the potential for CMX157, given its superior potency, to be more effective at lower doses and potentially reduce the risk of tenofovir-associated side effects. The study is expected to conclude in the fourth quarter of 2016.
CTRV: 1.08 (-0.04)
ContraVir Completes Merger with Ciclofilin Pharmaceuticals
PR Newswire - Mon Jun 13, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has completed its previously announced merger with Ciclofilin Pharmaceuticals, Inc., acquiring all of its outstanding equity interests. Ciclofilin's lead asset is CPI-431-32, which is in development against hepatitis B virus (HBV). CPI-431-32 strengthens ContraVir's HBV portfolio, which also contains CMX157, a highly potent HBV antiviral that works through a complementary mechanism.
CTRV: 1.08 (-0.04)
ContraVir Pharmaceuticals to Present at 2016 Biotechnology Innovation Organization International Convention
PR Newswire - Thu Jun 02, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the 2016 Biotechnology Innovation Organization (BIO) International Convention being held June 6 - 9, 2016 in San Francisco.
CTRV: 1.08 (-0.04)
ContraVir Initiates Head-to-Head Phase 2a Clinical Study of CMX157 vs. Viread® for Treating Hepatitis B
PR Newswire - Wed Jun 01, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that following a positive recommendation from an independent Data Safety Monitoring Board (DSMB), the Company has begun screening patients with chronic hepatitis B (HBV) for enrollment in a head-to-head Phase 2a study comparing ContraVir's CMX157 to tenofovir DF (TDF, marketed by Gilead Sciences as Viread®). The study will compare sequentially escalating doses of CMX157, beginning at a 5 mg daily CMX157 dose compared to 300 mg daily dose of TDF which is the standard daily dose of Viread®. The study is expected to conclude in the fourth quarter of 2016.
CTRV: 1.08 (-0.04)
ContraVir to Expand Hepatitis B Portfolio through Strategic Merger Agreement with Ciclofilin Pharmaceuticals
PR Newswire - Tue May 31, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has entered into a definitive merger agreement with privately-held Ciclofilin Pharmaceuticals, Inc. pursuant to which ContraVir will acquire all of the outstanding equity interests in Ciclofilin for the right to receive future milestone payments which will be allocated among the holders of Ciclofilin common stock. The milestone payments will consist of up to an aggregate $17 million cash and up to 10% of ContraVir's issued and outstanding common stock as of the closing date of the merger, and will be paid upon the achievement of certain developmental and/or regulatory milestones related to CPI-431-32, Ciclofilin's lead development candidate.
CTRV: 1.08 (-0.04)
ContraVir Pharmaceuticals to Present at 2016 Marcum MicroCap Conference
PR Newswire - Thu May 26, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at The 2016 Marcum MicroCap Conference being held June 1-2, 2016, at the Grand Hyatt New York in New York City.
CTRV: 1.08 (-0.04)
ContraVir to Showcase CMX157 Data in Poster at the 3rd ANRS HBV Cure Workshop
PR Newswire - Wed May 25, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will showcase key CMX157 data in a poster at the 3rd ANRS HBV Cure Workshop to be held Tuesday, May 31, 2016 at the UIC-Paris in Paris, France.
CTRV: 1.08 (-0.04)
ContraVir Doses First Subject in Phase 1b Clinical Study of CMX157 for Treating Chronic Hepatitis B Infection
PR Newswire - Tue Apr 19, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has dosed the first healthy volunteer in the Phase 1b portion of the Company's Phase 1b/2a multiple ascending dose clinical study of CMX157, ContraVir's novel, highly potent lipid conjugate of tenofovir for treating hepatitis B virus (HBV) infection.
CTRV: 1.08 (-0.04)
ContraVir Invited to Present CMX157 Data at Cambridge Healthtech Institute's Eleventh Annual Drug Discovery Chemistry Conference
PR Newswire - Thu Apr 14, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it was invited to present key CMX157 data at the Cambridge Healthtech Institute's Eleventh Annual Drug Discovery Chemistry Conference to be held April 19-22, 2016 at the Hilton San Diego Resort in San Diego, CA.
CTRV: 1.08 (-0.04)
Nasdaq and OTC Companies to Present Online to Investors on April 7
PR Newswire - Tue Apr 05, 1:38PM CDT
VirtualInvestorsConferences.com hosts CEOs: live questions answered during online roadshow and in virtual trade booths
CTRV: 1.08 (-0.04), GWGH: 6.82 (-0.03), RVLT: 6.99 (+0.49)
ContraVir Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com April 7
PR Newswire - Tue Apr 05, 5:00AM CDT
Company invites individual and institutional investors to attend interactive real-time virtual presentation
CTRV: 1.08 (-0.04)
ContraVir Pharmaceuticals, Inc. Announces Closing Of Public Offering Of Common Stock And Warrants
PR Newswire - Mon Apr 04, 2:02PM CDT
ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV) ("ContraVir" or the "Company"
, a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced the closing of its previously announced best efforts underwritten public offering of 4,929,578 shares of its common stock and warrants to purchase up to 2,464,789 shares of the Company's common stock at a fixed combined price to the public of $1.42. The shares of common stock and warrants were issued separately. The warrants are exercisable for a period of five years following the issuance thereof at an exercise price of $1.70 per share. There is no established public trading market for the warrants and ContraVir does not expect a market to develop in the future. The gross proceeds to ContraVir from this offering is $7,000,000, before deducting the underwriting discount and other estimated offering expenses payable by the Company.
CTRV: 1.08 (-0.04)
ContraVir Invited to Present CMX157 Data at the Oligonucleotide Therapeutics & Delivery Conference
PR Newswire - Mon Apr 04, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has been invited to present key CMX157 data at the Oligonucleotide Therapeutics & Delivery Conference to be held April 4-5, 2016 at the Hyatt Regency Cambridge in Cambridge, MA.
CTRV: 1.08 (-0.04)
ContraVir Pharmaceuticals Appoints John Cavan as Chief Financial Officer
PR Newswire - Thu Mar 31, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the appointment of John Cavan as Chief Financial Officer. Mr. Cavan had served as the Company's interim CFO since January 2016.
CTRV: 1.08 (-0.04)
ContraVir Pharmaceuticals, Inc. Pricing Underwritten Public Offering Of Common Stock And Warrants To Purchase Common Stock
PR Newswire - Wed Mar 30, 8:11AM CDT
ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV) ("ContraVir" or the "Company", a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced the pricing of a best efforts underwritten public offering of up to 4,929,578 shares of its common stock and warrants to purchase up to 2,464,789 shares of the Company's common stock at a fixed combined price to the public of $1.42. The shares of common stock and warrants will be issued separately. The warrants will be exercisable beginning on the date of issuance for a period of five years from the issuance date at an exercise price of $1.70 per share. There is no established public trading market for the warrants and ContraVir does not expect a market to develop in the future. The gross proceeds to ContraVir from this offering are expected to be $7,000,000, before deducting the underwriting discount and other estimated offering expenses payable by the Company. The offering is expected to close on or about April 4, 2016, subject to customary closing conditions.
CTRV: 1.08 (-0.04)
ContraVir Pharmaceuticals, Inc. Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock
PR Newswire - Tue Mar 29, 3:42PM CDT
ContraVir Pharmaceuticals, Inc. (Nasdaq:CTRV) ("ContraVir" or the "Company", a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in a "best efforts" underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
CTRV: 1.08 (-0.04)
Stocks to Buy: Four Stocks to Consider on (3/29/16)
ACCESSWIRE - Tue Mar 29, 9:29AM CDT
MIAMI, FL / ACCESSWIRE / March 28, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. RJETQ, COOL, KERX, and CTRV have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
CTRV: 1.08 (-0.04), COOL: 0.67 (-0.08), KERX: 6.89 (+0.08)
ContraVir's CMX157 Outperforms Gilead's Tenofovir AF (TAF) Against Hepatitis B Virus in Independent Head-to-Head In-Vitro Study
PR Newswire - Tue Mar 29, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, reported positive results from a third-party in vitro study that further validates CMX157's profile as a highly potent anti-hepatitis B drug. In this first head-to-head in vitro study, CMX157 compared favorably to tenofovir alafenamide fumarate (TAF), which was approved recently by the US Food and Drug Administration (FDA) as part of a four-drug combination therapy for HIV-1 (Genvoya®), and is currently under development by Gilead Sciences Inc. (GILD) for treating chronic hepatitis B infection. ContraVir recently initiated a Phase 1/2a clinical study of CMX157, which is currently enrolling healthy volunteers and is anticipated to begin enrolling hepatitis B patients in the second quarter 2016.
CTRV: 1.08 (-0.04)
Center Point Clinical Services Signs Partnership Agreement with ContraVir Pharmaceuticals
PR Newswire - Wed Jun 29, 6:00AM CDT
Center Point Clinical Services, provider of specialty clinical research solutions including the signature Clinical Trials Research Pharmacist (CTRP®) solution, announced today that it is renewing its partnering agreement with ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies. Under the terms of the agreement, Center Point will continue to provide its CTRP solution to support the clinical sites participating in ContraVir's Phase 3, randomized study of FV-100, in development as a fast-acting, low-dose, once-daily, oral antiviral therapy for the treatment of herpes zoster, or shingles.
CTRV: 1.08 (-0.04)
ContraVir Doses First Patients in Head-to-Head Study of CMX157 vs. Viread® for Treating Hepatitis B
PR Newswire - Tue Jun 21, 5:29AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has dosed the first patients with chronic hepatitis B in its head-to-head Phase 2a study comparing ContraVir's CMX157 to tenofovir DF (TDF, marketed by Gilead Sciences, Inc. as Viread®). The study is the first to directly compare lower doses of CMX157 to the standard daily dose of Viread in hepatitis B patients, and will evaluate the potential for CMX157, given its superior potency, to be more effective at lower doses and potentially reduce the risk of tenofovir-associated side effects. The study is expected to conclude in the fourth quarter of 2016.
CTRV: 1.08 (-0.04)
ContraVir Completes Merger with Ciclofilin Pharmaceuticals
PR Newswire - Mon Jun 13, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has completed its previously announced merger with Ciclofilin Pharmaceuticals, Inc., acquiring all of its outstanding equity interests. Ciclofilin's lead asset is CPI-431-32, which is in development against hepatitis B virus (HBV). CPI-431-32 strengthens ContraVir's HBV portfolio, which also contains CMX157, a highly potent HBV antiviral that works through a complementary mechanism.
CTRV: 1.08 (-0.04)
ContraVir Pharmaceuticals to Present at 2016 Biotechnology Innovation Organization International Convention
PR Newswire - Thu Jun 02, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the 2016 Biotechnology Innovation Organization (BIO) International Convention being held June 6 - 9, 2016 in San Francisco.
CTRV: 1.08 (-0.04)
ContraVir Initiates Head-to-Head Phase 2a Clinical Study of CMX157 vs. Viread® for Treating Hepatitis B
PR Newswire - Wed Jun 01, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that following a positive recommendation from an independent Data Safety Monitoring Board (DSMB), the Company has begun screening patients with chronic hepatitis B (HBV) for enrollment in a head-to-head Phase 2a study comparing ContraVir's CMX157 to tenofovir DF (TDF, marketed by Gilead Sciences as Viread®). The study will compare sequentially escalating doses of CMX157, beginning at a 5 mg daily CMX157 dose compared to 300 mg daily dose of TDF which is the standard daily dose of Viread®. The study is expected to conclude in the fourth quarter of 2016.
CTRV: 1.08 (-0.04)
ContraVir to Expand Hepatitis B Portfolio through Strategic Merger Agreement with Ciclofilin Pharmaceuticals
PR Newswire - Tue May 31, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has entered into a definitive merger agreement with privately-held Ciclofilin Pharmaceuticals, Inc. pursuant to which ContraVir will acquire all of the outstanding equity interests in Ciclofilin for the right to receive future milestone payments which will be allocated among the holders of Ciclofilin common stock. The milestone payments will consist of up to an aggregate $17 million cash and up to 10% of ContraVir's issued and outstanding common stock as of the closing date of the merger, and will be paid upon the achievement of certain developmental and/or regulatory milestones related to CPI-431-32, Ciclofilin's lead development candidate.
CTRV: 1.08 (-0.04)
ContraVir Pharmaceuticals to Present at 2016 Marcum MicroCap Conference
PR Newswire - Thu May 26, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at The 2016 Marcum MicroCap Conference being held June 1-2, 2016, at the Grand Hyatt New York in New York City.
CTRV: 1.08 (-0.04)
ContraVir to Showcase CMX157 Data in Poster at the 3rd ANRS HBV Cure Workshop
PR Newswire - Wed May 25, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will showcase key CMX157 data in a poster at the 3rd ANRS HBV Cure Workshop to be held Tuesday, May 31, 2016 at the UIC-Paris in Paris, France.
CTRV: 1.08 (-0.04)
ContraVir Doses First Subject in Phase 1b Clinical Study of CMX157 for Treating Chronic Hepatitis B Infection
PR Newswire - Tue Apr 19, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has dosed the first healthy volunteer in the Phase 1b portion of the Company's Phase 1b/2a multiple ascending dose clinical study of CMX157, ContraVir's novel, highly potent lipid conjugate of tenofovir for treating hepatitis B virus (HBV) infection.
CTRV: 1.08 (-0.04)
ContraVir Invited to Present CMX157 Data at Cambridge Healthtech Institute's Eleventh Annual Drug Discovery Chemistry Conference
PR Newswire - Thu Apr 14, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it was invited to present key CMX157 data at the Cambridge Healthtech Institute's Eleventh Annual Drug Discovery Chemistry Conference to be held April 19-22, 2016 at the Hilton San Diego Resort in San Diego, CA.
CTRV: 1.08 (-0.04)
Nasdaq and OTC Companies to Present Online to Investors on April 7
PR Newswire - Tue Apr 05, 1:38PM CDT
VirtualInvestorsConferences.com hosts CEOs: live questions answered during online roadshow and in virtual trade booths
CTRV: 1.08 (-0.04), GWGH: 6.82 (-0.03), RVLT: 6.99 (+0.49)
ContraVir Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com April 7
PR Newswire - Tue Apr 05, 5:00AM CDT
Company invites individual and institutional investors to attend interactive real-time virtual presentation
CTRV: 1.08 (-0.04)
ContraVir Pharmaceuticals, Inc. Announces Closing Of Public Offering Of Common Stock And Warrants
PR Newswire - Mon Apr 04, 2:02PM CDT
ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV) ("ContraVir" or the "Company"
, a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced the closing of its previously announced best efforts underwritten public offering of 4,929,578 shares of its common stock and warrants to purchase up to 2,464,789 shares of the Company's common stock at a fixed combined price to the public of $1.42. The shares of common stock and warrants were issued separately. The warrants are exercisable for a period of five years following the issuance thereof at an exercise price of $1.70 per share. There is no established public trading market for the warrants and ContraVir does not expect a market to develop in the future. The gross proceeds to ContraVir from this offering is $7,000,000, before deducting the underwriting discount and other estimated offering expenses payable by the Company. CTRV: 1.08 (-0.04)
ContraVir Invited to Present CMX157 Data at the Oligonucleotide Therapeutics & Delivery Conference
PR Newswire - Mon Apr 04, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has been invited to present key CMX157 data at the Oligonucleotide Therapeutics & Delivery Conference to be held April 4-5, 2016 at the Hyatt Regency Cambridge in Cambridge, MA.
CTRV: 1.08 (-0.04)
ContraVir Pharmaceuticals Appoints John Cavan as Chief Financial Officer
PR Newswire - Thu Mar 31, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the appointment of John Cavan as Chief Financial Officer. Mr. Cavan had served as the Company's interim CFO since January 2016.
CTRV: 1.08 (-0.04)
ContraVir Pharmaceuticals, Inc. Pricing Underwritten Public Offering Of Common Stock And Warrants To Purchase Common Stock
PR Newswire - Wed Mar 30, 8:11AM CDT
ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV) ("ContraVir" or the "Company"
, a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced the pricing of a best efforts underwritten public offering of up to 4,929,578 shares of its common stock and warrants to purchase up to 2,464,789 shares of the Company's common stock at a fixed combined price to the public of $1.42. The shares of common stock and warrants will be issued separately. The warrants will be exercisable beginning on the date of issuance for a period of five years from the issuance date at an exercise price of $1.70 per share. There is no established public trading market for the warrants and ContraVir does not expect a market to develop in the future. The gross proceeds to ContraVir from this offering are expected to be $7,000,000, before deducting the underwriting discount and other estimated offering expenses payable by the Company. The offering is expected to close on or about April 4, 2016, subject to customary closing conditions. CTRV: 1.08 (-0.04)
ContraVir Pharmaceuticals, Inc. Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock
PR Newswire - Tue Mar 29, 3:42PM CDT
ContraVir Pharmaceuticals, Inc. (Nasdaq:CTRV) ("ContraVir" or the "Company"
, a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in a "best efforts" underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. CTRV: 1.08 (-0.04)
Stocks to Buy: Four Stocks to Consider on (3/29/16)
ACCESSWIRE - Tue Mar 29, 9:29AM CDT
MIAMI, FL / ACCESSWIRE / March 28, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. RJETQ, COOL, KERX, and CTRV have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
CTRV: 1.08 (-0.04), COOL: 0.67 (-0.08), KERX: 6.89 (+0.08)
ContraVir's CMX157 Outperforms Gilead's Tenofovir AF (TAF) Against Hepatitis B Virus in Independent Head-to-Head In-Vitro Study
PR Newswire - Tue Mar 29, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, reported positive results from a third-party in vitro study that further validates CMX157's profile as a highly potent anti-hepatitis B drug. In this first head-to-head in vitro study, CMX157 compared favorably to tenofovir alafenamide fumarate (TAF), which was approved recently by the US Food and Drug Administration (FDA) as part of a four-drug combination therapy for HIV-1 (Genvoya®), and is currently under development by Gilead Sciences Inc. (GILD) for treating chronic hepatitis B infection. ContraVir recently initiated a Phase 1/2a clinical study of CMX157, which is currently enrolling healthy volunteers and is anticipated to begin enrolling hepatitis B patients in the second quarter 2016.
CTRV: 1.08 (-0.04)
